OpenEvidence

The Financial Times reported on 2026-10-21 that OpenEvidence is on track for $400 million to $500 million in advertising revenue this year, according to a source. The company says nearly two-thirds of the roughly one million US physicians use its free AI search tool. OpenEvidence was valued at $15 billion after raising $250 million in September 2026. The figures are a new revenue disclosure that underpins its $15 billion valuation and its ad-funded model.

Source: Financial Times

Anthropic and medical knowledge platform OpenEvidence said on September 22, 2026 that they are collaborating to deliver AI-powered clinical decision support free to healthcare providers in low- and middle-income countries, Reuters reported exclusively. The initiative is a specialised version of OpenEvidence rolling out in about 100 countries including Uganda, Angola, Sudan, Haiti and Mongolia, per a list provided by OpenEvidence; the platform is already free to clinicians in the US and Europe. The deal pushes Claude into clinical workflows across a new set of geographies and builds Anthropic's healthcare vertical ahead of its IPO.

Source: Reuters

Sacra estimates that OpenEvidence hit $300M in annualized revenue in July 2026, up from $150M at the end of 2025.

Source: Sacra

On Sep 11, 2026 OpenEvidence and MINC#NIMC, the federally incorporated not-for-profit that issues lifetime physician identifiers in Canada (founded by the Federation of Medical Regulatory Authorities of Canada and the Medical Council of Canada), announced a partnership letting Canadian physicians verify with their MINC number for continued free access to OpenEvidence. The company said its platform is already used by more than 50% of physicians in Canada; CEO Daniel Nadler said keeping it free for Canadian doctors is personal to him. It formalizes OpenEvidence's first major international distribution channel and discloses a striking penetration metric.

Source: Unite.AI